Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01040858
Other study ID # D7217-R
Secondary ID IRB#2277
Status Completed
Phase N/A
First received December 28, 2009
Last updated January 14, 2015
Start date May 2011
Est. completion date September 2013

Study information

Verified date January 2015
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

The number of OEF/OIF veterans seeking care and rehabilitation services within the VA Health Care System is increasing rapidly. The cognitive effects of MTBI are clinically significant and can adversely affect a veteran's ability to reintegrate into civilian life, return to duty, succeed in competitive employment, or function independently. The primary product of the proposed study would be an empirically validated, manualized, cognitive rehabilitation intervention for OIF/OIF veterans with cognitive disorders. The group treatment modality has the virtue of efficiency and a manualized treatment approach would allow wide-ranging application throughout the VHA system. As such, the proposed study is likely to have a significant effect on the quality and effectiveness of rehabilitative services being offered to our returning soldiers with combat-related MTBI and cognitive impairment.


Description:

As a result of the current military operations in Afghanistan (Operation Enduring Freedom; OEF) and Iraq (Operation Iraqi Freedom; OIF), the Department of Veterans Affairs (VA) is providing health care for increasing numbers of veterans who have experienced mild traumatic brain injury (MTBI) or concussion, many of whom complain of cognitive impairment. MTBI is the most common combat-related injury and can occur with or without direct impact, obvious external injuries, or loss of consciousness. Currently, cognitive rehabilitation for MTBI typically includes training in compensatory strategies that help patients develop internal strategies (e.g., visual imagery) and utilize external aides (e.g., memory notebooks, calendars/organizers, timers) to compensate for cognitive deficits. Initial data from our unfunded cognitive rehabilitation pilot study are encouraging and indicate post-treatment improvement on multiple outcome measures. However, to date, no published studies have evaluated the efficacy of specific cognitive rehabilitation interventions with OEF/OIF veterans who have experienced combat-related MTBI. The primary objective of this study, therefore, is to evaluate the efficacy of a manualized, 10-week, Compensatory Strategy Training (CST) intervention for OEF/OIF veterans with cognitive disorder resulting from the aftereffects of combat-related mild traumatic brain injury. The specific goals are: 1) to determine the efficacy of cognitive rehabilitation group treatment; and 2) to determine the treatment factors and patient characteristics that are associated with improved functional outcomes. The overall goal is to develop an evidence-based, manualized, group treatment that can be readily implemented in VHA treatment settings. The study design makes use of the convergent availability of resources available at the four participating VAs in Portland Oregon, Puget Sound Washington, San Diego California, and Boise Idaho. The study will recruit a total of 280 OEF/OIF veterans enrolled for medical services at these VAs. In a randomized controlled trial, we will compare two groups: eligible participants will be randomly assigned to either the Cognitive Strategy Training (CST) group or Usual Care (UC) group. Participants in the CST group will receive the CST intervention during their participation in the study, which will consist of weekly 120-minute group sessions for 10 weeks as guided by the CST Treatment Manual. UC participants will continue to receive usual care (i.e., their regular medical, psychiatric, and psychotherapeutic care; no CST intervention) during their participation, but will be offered CST after the end of the study. Both groups will undergo assessments at baseline, 5 weeks (midway through CST),10 weeks (immediately following the end of CST), and 15 weeks (5 weeks after CST is completed). These assessments will include a brief cognitive assessment battery and a battery of questionnaires and paper-pencil tests designed to assess current psychological and cognitive symptom severity, utility of compensatory strategies, self-efficacy, adaptive functioning, ability to reliably manage personal affairs, substance use, quality of life, and treatment satisfaction ratings. During their study participation, all participants will continue to receive their regular medical, psychiatric, and psychotherapeutic care.


Recruitment information / eligibility

Status Completed
Enrollment 128
Est. completion date September 2013
Est. primary completion date May 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- OEF/OIF veterans enrolled at a participating VA who are able to provide informed consent; and

- As part of standard VA clinical care, have screened positive for MTBI and complain of cognitive impairment.

Exclusion Criteria:

- Current substance use disorder with less than 30 days abstinence;

- History of a primary psychotic disorder; and

- Auditory or visual impairments that would prevent ability to participate in the cognitive rehabilitation group or benefit from compensatory strategies.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Strategy Training
Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
Other:
Placebo comparison group
Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).

Locations

Country Name City State
United States VA Medical Center, Boise Boise Idaho
United States VA Medical Center, Portland Portland Oregon
United States VA San Diego Healthcare System, San Diego San Diego California
United States VA Puget Sound Health Care System, Seattle Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Multiple Sclerosis Neuropsychological Screening Questionnaire-Patient Version A self-report measure of severity of attention and organizational problems. It measures the sum of severity ratings on a scale from 0 (never) to 4 (very often). The total score ranges from 0 to 64. Week 10 No
Secondary Prospective-Retrospective Memory Questionnaire (PRMQ; Crawford, Henry, Ward, & A 16-item self-report severity measure of prospective and retrospective memory problems relevant to everyday life. The measure reports the sum of severity ratings on a scale from 1 (never) to 5 (very often). The PRMQ total score ranges from 16 to 80. Week 10 No
Secondary The Neurobehavioral Symptom Inventory A post-concussive symptom measure. The total score on the measure is the sum of severity ratings for 22 symptoms on a scale from 0 (none) to 4 (very severe). NSI total score ranges from 0 to 88. Week 10 No
Secondary Memory Compensation Questionnaire The MCQ is a 44-item self-report questionnaire that rates the extent to which patients use various strategies to improve memory performance relevant to daily living. The MCQ measures the sum of memory strategies used on a scale from 0 (never) to 4 (always). The total score ranges from 0 to 176. Week 10 No
Secondary Hopkins Verbal Memory Test-Revised Verbal list learning and delayed recall. Total recall T-score was used for the analyses. Total recall T-score ranges from 13 (severely impaired) to 86 (very superior). Week 10 No
Secondary Wechsler Adult Intelligence Scale-3rd Edition, Digit Span Subtest A measure of attention and working memory. Total score was used, and it ranges from 0 to 48, with higher scores indicating greater attentional capacity. Week 10 No
Secondary Delis-Kaplan Executive Function System, Trails Subtest A visual-motor task used to measure flexibility in thinking (executive function) and processing speed. Scaled score for Condition 4 was used, and possible scores ranges from 0 to 20 with higher scores indicating better outcome. Week 10 No
Secondary Delis-Kaplan Executive Function System, Verbal Fluency Subtest A measure of verbal fluency, generativity, and processing speed. A scaled score of Letter Fluency portion of the test was used. The scores ranged from 0 to 20 with higher scores indicating better outcomes. Week 10 No
Secondary PTSD Checklist-Military Version A PTSD symptom severity measures based on DSM-IV diagnostic criteria. It measures the sum of severit ratings for 17 symptoms on a scale from 1 (not at all) to 5 (extremely). PCL-M total score ranges from 17 to 85. Week 10 No
Secondary Beck Depression Inventory, Second Edition A depression symptom severity measures based on DSM-IV diagnostic criteria. It measures the sum of severity ratings for 21 symptoms on a scale from 0 (none) to 3 (severe). BDI total score ranges from 0 to 63. Week 10 No
Secondary Severity of Dependence Scale A brief substance dependence measure. It measures the sum of severity ratings for 5 symptoms on a scale from 0 (never) to 3 (always). The total score ranges from 0 15. Week 10 No
Secondary Satisfaction With Life Scale A brief measure of global life satisfaction. It measures the sum of satisfaction ratings for 5 items on a scale from 1 (strongly disagree) to 7 (strongly agree). The total score ranges from 5 to 35 with higher scores indicating greater satifaction. Week 10 No
See also
  Status Clinical Trial Phase
Completed NCT02488720 - Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study
Recruiting NCT03544801 - Renji Cerebral Small Vessel Disease Corhort Study
Recruiting NCT02813434 - Cerebral Amyloid Imaging Using Florbetapir (AV-45) Phase 3
Completed NCT00400790 - Organ Protection for Coronary Artery Bypass Graft (CABG): Propofol Versus Desflurane N/A
Completed NCT00052091 - Therapy for Depressed Elders With Thought Problems Phase 3
Completed NCT00267163 - Brain Imaging and Mental Disorders of Aging Intervention Phase 4
Completed NCT00021866 - Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy N/A
Not yet recruiting NCT04079075 - Multiple Interventions to Prevent Cognitive Decline N/A
Terminated NCT03696082 - A Precision Rehabilitation Approach to Counteract Age-Related Cognitive Declines N/A
Completed NCT02918539 - Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
Active, not recruiting NCT01708837 - Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction Phase 4
Completed NCT01290939 - Bevacizumab and Lomustine for Recurrent GBM Phase 3
Terminated NCT00548327 - The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype Phase 2
Unknown status NCT00256425 - Cognitive Rehabilitation of Glioma Patients Phase 3
Recruiting NCT03926351 - High Dose Omega 3 in People at Risk for Dementia Phase 2
Completed NCT02118571 - Schizophrenia Cognition Scale Development N/A
Completed NCT01481961 - Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease N/A
Completed NCT00788918 - Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS) N/A
Completed NCT00564902 - The Zeaxanthin and Visual Function Study N/A
Completed NCT00529581 - A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis Phase 2